RT Journal Article
SR Electronic
T1 Increased amygdala volume and functional connectivity with cognitive control networks in chronic migraine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.31.20185397
DO 10.1101/2020.08.31.20185397
A1 DeSouza, Danielle D.
A1 Krimmel, Samuel R.
A1 Sanjanwala, Bharati M.
A1 Peretz, Addie
A1 Menon, Vinod
A1 Seminowicz, David A.
A1 Cowan, Robert P.
YR 2020
UL http://medrxiv.org/content/early/2020/09/02/2020.08.31.20185397.abstract
AB Objective To characterize the role of the amygdala in episodic (EM) and chronic (CM) migraine, we evaluated amygdala volumes, functional connectivity (FC), and associations with clinical and affective measures.Methods Eighty-eight patients (44 with EM and 44 age- and sex-matched patients with CM) completed anatomical and resting-state functional MRI scans. Amygdala volumes and resting-state FC to three core large-scale cognitive control networks (default mode (DMN), salience (SN), central executive (CEN)) were compared between groups. Associations between amygdala volume and FC, measures of headache severity (frequency and intensity), and cognitive-affective measures (depression, anxiety, pain catastrophizing) were evaluated.Results Compared to EM, patients with CM had larger amygdala volume bilaterally. Headache frequency and intensity were associated with increased left and right amygdala volume, and depression was associated with increased right amygdala volume. Patients with CM also demonstrated increased left amygdala FC with the DMN, which across patients was related to headache frequency. Left amygdala FC to the SN was correlated with headache intensity while right amygdala FC to the CEN was correlated with pain catastrophizing.Conclusion Our findings reveal increased amygdala volume and FC with large-scale neurocognitive networks in patients with CM compared to EM. Aberrant amygdala volume and FC measures were associated with increased migraine severity, depression, and pain catastrophizing, pointing to a link between emotion and pain in migraine. Our findings provide novel insights into amygdala involvement in chronic migraine and may inform future interventions aimed at preventing the progression of both headache and its negative cognitive-affective symptoms.Competing Interest StatementNo competing interests for DDD, SRK, BMS, AP, VM, and DAS. RPC is an advisor (unrelated to current study) for Alder, Amgen, Allergan, Biohaven, Curex, Teva, and Xoc.Clinical TrialNCT03231241Funding StatementThis work was supported by the SunStar Foundation to R.P. Cowan and NCCIH/NIH R01 AT007176 to D.A. Seminowicz.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Both Stanford University and the University of Maryland, Baltimore received institutional IRB approval. Data sharing between institutions was permitted via a Data Transfer and Use Agreement (AGR760476).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data can be shared upon request from qualified investigators.